Depo-Provera Use and Bone Health Considerations
Current Guideline Position on Duration of Use
- The American College of Obstetricians and Gynecologists (ACOG) does not advise limiting DMPA use to 2 years, and does not recommend routinely monitoring bone density after that timeframe 1, 2
- The American College of Obstetricians and Gynecologists (ACOG) recommends individualized decision-making for extended use beyond 2 years, considering bone health 1, 2
Bone Health Considerations
- DMPA causes reductions in bone mineral density during use, which is the primary concern for extended therapy 1, 2
- Substantial recovery of BMD occurs after discontinuation in adult women, with partial recovery toward baseline by 2 years post-treatment at the total hip, femoral neck, and lumbar spine 1, 2
- The typical use failure rate of DMPA is approximately 6% in the first year 1
Bone Health Optimization Strategy
- All patients should be counseled about measures that promote skeletal health, including daily intake of 1300 mg calcium 1, 2, 3
- All patients should be counseled about measures that promote skeletal health, including daily intake of 600 IU vitamin D 1, 2, 3
- All patients should be counseled about measures that promote skeletal health, including regular weight-bearing exercise 1, 2, 3
- Smoking cessation is recommended, as tobacco use compounds bone loss risk 3
- Alcohol avoidance or minimization is recommended 3
Alternative Contraceptive Considerations
- Other birth control methods should be considered in the risk/benefit analysis if bone health concerns are significant or the patient has multiple osteoporosis risk factors 1, 2
Common Pitfalls to Avoid
- Do not automatically discontinue DMPA at 2 years without considering the patient's contraceptive needs and alternative options 1, 2
- Do not order routine DEXA scans in otherwise healthy women using DMPA, as there is no evidence supporting this practice 3
- Do not fail to counsel on modifiable risk factors, which are the primary interventions available to maintain bone health in DMPA users 3
- Do not ignore individual risk stratification—tailor counseling and recommendations to each patient's specific osteoporosis risk profile 1